The Duke CSF-Venous Fistula Confidence Score: Real-World Application on CT Myelography.

AJNR Am J NeuroradiolOct 1, 2026 (epub)
Case ReportRadiology (Diagnostic)

Timothy J Amrhein, Daphne Zhu, Ajay A Madhavan et al.

✦ AI-curated · Sources linked

Case in brief

A case of a patient with spontaneous intracranial hypotension was evaluated using CT myelography to identify a suspected CSF-venous fistula (CVF). The application of the Duke CSF-Venous Fistula Confidence Score (DCCS) facilitated a structured assessment of imaging findings, ultimately aiding in the determination of the presence of a CVF. The case illustrates the practical utility of the DCCS in clinical settings.

Diagnostic / clinical pearl

The Duke CSF-Venous Fistula Confidence Score provides a structured approach to assess the likelihood of CSF-venous fistulas during CT myelography, enhancing diagnostic accuracy.

Source

PubMed · PMID 42323196

Published in AJNR Am J Neuroradiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.